[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2018005071A - Tratamiento del cancer de pulmon de celulas pequeñas con un inhibidor de parp. - Google Patents

Tratamiento del cancer de pulmon de celulas pequeñas con un inhibidor de parp.

Info

Publication number
MX2018005071A
MX2018005071A MX2018005071A MX2018005071A MX2018005071A MX 2018005071 A MX2018005071 A MX 2018005071A MX 2018005071 A MX2018005071 A MX 2018005071A MX 2018005071 A MX2018005071 A MX 2018005071A MX 2018005071 A MX2018005071 A MX 2018005071A
Authority
MX
Mexico
Prior art keywords
treatment
lung cancer
small cell
cell lung
parp inhibitor
Prior art date
Application number
MX2018005071A
Other languages
English (en)
Inventor
Feng Ying
E Post Leonard
Shen Yuqiao
Ru Yuanbin
Wang Evelyn
Yu Karen
Original Assignee
Medivation Tech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivation Tech Llc filed Critical Medivation Tech Llc
Publication of MX2018005071A publication Critical patent/MX2018005071A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)

Abstract

Se describen métodos para el tratamiento de un sujeto con cáncer de pulmón de células pequeñas que expresa Schlafen-11 (SLFN 11) con un inhibidor de poli(ADP-ribosa) polimerasas (PARP) o una sal farmacéuticamente aceptable del mismo. Específicamente, el método comprende la detección de SLFN 11 en una muestra de células tumorales del sujeto, y la administración al sujeto de una cantidad eficaz de un inhibidor de PARP, tal como talazoparib o la sal de tosilato de talazoparib.
MX2018005071A 2015-10-26 2016-10-26 Tratamiento del cancer de pulmon de celulas pequeñas con un inhibidor de parp. MX2018005071A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562246538P 2015-10-26 2015-10-26
PCT/US2016/058928 WO2017075091A1 (en) 2015-10-26 2016-10-26 Treatment of small cell lung cancer with a parp inhibitor

Publications (1)

Publication Number Publication Date
MX2018005071A true MX2018005071A (es) 2018-11-29

Family

ID=58631864

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005071A MX2018005071A (es) 2015-10-26 2016-10-26 Tratamiento del cancer de pulmon de celulas pequeñas con un inhibidor de parp.

Country Status (13)

Country Link
US (1) US20190054087A1 (es)
EP (1) EP3368041A4 (es)
JP (1) JP2018536700A (es)
KR (1) KR20180100546A (es)
CN (1) CN108883115A (es)
AU (1) AU2016346351A1 (es)
BR (1) BR112018008503A2 (es)
CA (1) CA3003422A1 (es)
IL (1) IL258900A (es)
MX (1) MX2018005071A (es)
RU (1) RU2018119128A (es)
SG (1) SG11201803462PA (es)
WO (1) WO2017075091A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3519051B1 (en) 2016-09-27 2021-09-22 Beigene, Ltd. Treatment of cancers using combination comprising parp inhibitors
MX2019013755A (es) 2017-05-18 2020-07-20 Tesaro Inc Terapias de combinación para el tratamiento del cáncer.
WO2018237034A1 (en) * 2017-06-20 2018-12-27 Nantomics, Llc QUANTIFICATION OF SLFN11 PROTEIN FOR OPTIMAL ANTICANCER THERAPY
AU2018302999A1 (en) * 2017-07-17 2020-01-30 Beigene, Ltd. Treatment cancers using a combination comprising PARP inhibitors, temozolomide and/or radiation therapy
EP3697442A4 (en) 2017-09-30 2021-07-07 Tesaro, Inc. COMBINATION THERAPIES FOR TREATMENT OF CANCER
EP3691685A1 (en) 2017-10-06 2020-08-12 Tesaro Inc. Combination therapies and uses thereof
CA3078806A1 (en) 2017-10-13 2019-04-18 Merck Patent Gmbh Combination of a parp inhibitor and a pd-1 axis binding antagonist
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
CA3087060A1 (en) * 2017-12-27 2019-07-04 Tesaro, Inc. Methods of treating cancer
WO2020095184A1 (en) 2018-11-05 2020-05-14 Pfizer Inc. Combinations for treating cancer
EP4118105A2 (en) 2020-03-09 2023-01-18 Pfizer Inc. Cd80-fc fusion protein and uses thereof
MX2023005641A (es) 2020-11-13 2023-05-24 Pfizer Forma de dosificacion en capsula de gelatina blanda de talazoparib.
CN116802321A (zh) 2020-12-07 2023-09-22 辉瑞公司 鉴定对他拉唑帕尼治疗敏感的肿瘤的方法以及其治疗方法
EP4304652A1 (en) * 2021-03-10 2024-01-17 Board of Regents, The University of Texas System Methods for treating small cell lung cancer and other neuroendocrine cancers
US20240180906A1 (en) 2021-03-24 2024-06-06 Pfizer Inc. Combination of Talazoparib and an Anti-Androgen for the Treatment of DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer
WO2023131894A1 (en) 2022-01-08 2023-07-13 Pfizer Inc. Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof
TW202425975A (zh) 2022-10-02 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
WO2024090805A1 (ko) * 2022-10-27 2024-05-02 이원다이애그노믹스(주) 폐암 진단용 메틸화 마커 및 이의 조합
TW202425976A (zh) 2022-12-17 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2393364A4 (en) * 2009-02-04 2013-03-13 Bipar Sciences Inc TREATMENT OF LUNG CANCER WITH A PARP INHIBITOR IN COMBINATION WITH A GROWTH FACTOR INHIBITOR
EP2531033A4 (en) * 2010-02-03 2013-07-31 Biomarin Pharm Inc POLY (ADP-RIBOSE) POLYMERASE (PARP) DIHYDROPYRIDOPHTHALAZINE HEMMER FOR USE IN THE TREATMENT OF PTEN-LACK ASSOCIATED DISEASES
US20130317027A1 (en) * 2010-03-01 2013-11-28 Myrexis, Inc. Compounds and therapeutic uses thereof
AR083502A1 (es) * 2010-10-21 2013-02-27 Biomarin Pharm Inc Sal tosilada de (8s,9r)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-dihidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona cristalina
CA2919498C (en) * 2013-07-31 2023-07-25 Windward Pharma, Inc. Aerosol nintedanib compounds and uses thereof

Also Published As

Publication number Publication date
RU2018119128A (ru) 2019-11-28
CN108883115A (zh) 2018-11-23
KR20180100546A (ko) 2018-09-11
IL258900A (en) 2018-06-28
EP3368041A4 (en) 2019-07-17
RU2018119128A3 (es) 2020-03-03
US20190054087A1 (en) 2019-02-21
BR112018008503A2 (pt) 2018-10-23
AU2016346351A1 (en) 2018-05-24
WO2017075091A1 (en) 2017-05-04
CA3003422A1 (en) 2017-05-04
SG11201803462PA (en) 2018-05-30
JP2018536700A (ja) 2018-12-13
EP3368041A1 (en) 2018-09-05

Similar Documents

Publication Publication Date Title
MX2018005071A (es) Tratamiento del cancer de pulmon de celulas pequeñas con un inhibidor de parp.
MX2017015473A (es) Tratamiento contra el cancer por manipulacion de la microflora comensal.
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
MX2020010194A (es) Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas.
EA201790398A1 (ru) Способы лечения заболевания печени
WO2016025635A3 (en) Combination therapy for treating cancer
MY184332A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
MX2018003657A (es) Metodo para tratar cancer usando una combinacion de agentes que dañan el adn e inhibidores de proteina relacionada con ataxia telangiectasia y rad3 (atr).
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
MX2016013600A (es) Método para tratar adenocarcinoma de pulmón.
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
EA201591924A1 (ru) Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
WO2016043874A3 (en) Combination therapy for treating cancer
MX2017014641A (es) Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa).
HK1251168A1 (zh) 用於治療和/或預防腫瘤的沙粒病毒和產生具有(改善的)腫瘤消退特性的沙粒病毒的方法
MX2016016388A (es) Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña.
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
WO2014151606A3 (en) Methods of treating pancreatic cancer
IL276406A (en) Osimertinib for use in the treatment of non-small cell lung cancer
WO2017069288A8 (en) Pharmaceutical composition for use in treating aml and method of treating aml in a subject in need thereof
DK3250711T3 (da) Fremgangsmåde og produkt til at forhindre falske positiver i fremgangsmåder anvendende ddntp'er
SG10201811078XA (en) Method Of Treatment Of Hypoxia Inducible Factor (HIF)-Related Conditions